| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | We have observed highly elevated levels of all four isoforms of p38 MAPK in serum of HNSCC patients compared to the control group. | 29747487 | 2019 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | Finally, we demonstrated that overexpressed PRRX1 was closely correlated with miR-642b-3p downregulation and the upregulation of TGF-β2 and p38 in a xenograft model of HNSCC. | 30622052 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | This study demonstrated that p38 MAPK activation may play a role in therapeutic resistance and disease relapse in HNSCC by maintenance of CSCs phenotype. | 29575240 | 2018 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC. | 28915597 | 2017 | ||||
|
0.080 | Biomarker | disease | BEFREE | p38 inhibitor treated and p38 shRNA HNSCC cell lines demonstrate a significant upregulation in E-cadherin mRNA and a decrease in the mRNA expression of Snail. p38 binds to and stabilizes p38IP, a subunit of histone SPT3-TAF9-GCN5 acetyltransferase (STAGA), resulting in enhanced transcription of Snail. p38 shRNA HNSCC cell lines show a less invasive phenotype in a spheroid model. | 27531877 | 2016 | ||||
|
0.080 | Biomarker | disease | BEFREE | Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN. | 24568968 | 2014 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | Since our previous data determined p38 MAPK to be a potent regulator of interleukin-6 (IL-6) and IL-8 expression in permanent head and neck squamous cell carcinoma (HNSCC) cell lines, we investigated the influence of this pathway on STAT3 and STAT1. | 22110204 | 2011 | ||||
|
0.080 | Biomarker | disease | BEFREE | We found that the blocking activation of ERK and/or p38 could reverse the celecoxib-induced cell growth inhibition by 50-80% in HNSCC cell lines, but it was not tested in cancer cells of other types. | 20717005 | 2010 |